XML 32 R18.htm IDEA: XBRL DOCUMENT
v3.23.3

ACQUISITION | 12 Months Ended
--- | ---
Aug. 31, 2023
Business Combination and Asset Acquisition [Abstract] |
ACQUISITION | ACQUISITION On June 16, 2023, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Insight Merger Sub, Inc., a wholly-owned subsidiary of the Company (“Merger Sub”), Immunetrics, a company specializing in quantitative systems pharmacology modeling, and LaunchCyte LLC, as representative of the stockholders of Immunetrics (the “Stockholder Representative”). At closing of the Merger, certain key stockholders of Immunetrics delivered executed Joinder Agreements, pursuant to which they became parties to the Merger Agreement. The Merger closed on June 16, 2023 (the “Closing”). Pursuant to the Merger Agreement, at Closing, Merger Sub merged with and into Immunetrics through a reverse triangular merger, with Immunetrics surviving as a wholly-owned subsidiary of the Company (the “Surviving Corporation”) (the “Merger”). As consideration for the Merger, the Company agreed to pay the stockholders, former holders of stock options and former holders of phantom shares of Immunetrics (collectively, the “Equityholders”) the following cash compensation (collectively, the “Merger Consideration”): i.At Closing, a cash payment in the amount of $13,705,083 (i.e., $12.0 million plus Immunetrics’ Closing cash, net of estimated net working capital adjustments at Closing, minus Immunetrics’ estimated transaction expenses, minus the Closing estimated indebtedness, minus the Holdback Amount (as defined below), minus the Stockholder Representative Expense Fund (as defined below)); ii.An amount equal to $1.8 million, which was held-back by the Company at Closing, to cover any negative net working capital adjustments (if any) and Immunetrics’ indemnification obligations under the Merger Agreement (the “Holdback Amount”); and iii.Two future earn-out payments in the aggregate amount of up to $8.0 million (the “Earnout Payments”), subject to the terms described below. Additionally, at Closing, the Company funded the payment of Stockholder Representative $250,000 as an expense fund to cover expenses that it incurs in its role as Stockholder Representative (the “Stockholder Representative Expense Fund”), the excess amount of which, if any, will be distributed to Immunetrics’ stockholders (subject to certain exceptions) at such time as the Stockholder Representative may determine in its sole discretion. The Company deducted this payment from the closing price. The Merger Consideration is subject to adjustment based on post-closing adjustments to net working capital, closing cash, indebtedness, and transaction expenses of Immunetrics within 90 days of closing. The Merger Agreement contains standard representations, warranties, covenants, indemnification and other terms customary in similar transactions. Concurrently with execution of the Merger Agreement, the Company, Merger Sub, Immunetrics and the Stockholder Representative entered into an Earnout Agreement, which sets forth the terms and conditions applicable to the Earnout Payments. Pursuant to the Earnout Agreement, the Company shall pay the Equityholders an aggregate amount of up to $8.0 million of Earnout Payments if the Surviving Corporation achieves certain revenue milestones for the calendar years 2023 and 2024. The primary purpose of this acquisition is to be able to capitalize on a tremendous growth opportunity by providing support for quantitative systems pharmacology (“QSP”) in a greater range of therapeutic areas, including oncology. Under the acquisition method of accounting, the total purchase price reflects Immunetrics’ tangible and intangible assets and liabilities based on their estimated fair values at the date of the completion of the acquisition (June 16, 2023). The following table summarizes the allocation of the preliminary purchase price for Immunetrics:
(in thousands) |  |
Base merger consideration |  | $ | 12,000 |
Fair value of earnout |  | 4,100 |
Cash on hand |  | 1,247 |
Adjustment to purchase price for closing indebtedness |  | (122) |
Net working capital adjustment |  | (377) |
D&O Tail |  | (7) |
Bonus compensation to Immunetrics staff |  | (1,586) |
Total purchase price |  | 15,255 |
Fair value of identifiable assets acquired: |  |
Cash |  | 1,132 |
Accounts receivable |  | 511 |
Security deposit |  | 12 |
ROU asset |  | 227 |
Deferred tax assets |  | 799 |
Trade names |  | 1,800 |
Customer relationships |  | 3,780 |
Developed Tech |  | 1,080 |
Non-competes |  | 30 |
|  | 9,371 |
Fair value of liabilities assumed: |  |
Lease liability |  | 227 |
Selling shareholders' D&O tail responsibility |  | 7 |
Deferred revenue |  | 60 |
|  | 294 |
Fair value of identifiable assets acquired and liabilities assumed |  | 9,077 |
Goodwill |  | $ | 6,178 |
The total purchase consideration related to Immunetrics acquisition consisted of cash consideration. The excess of purchase consideration over the fair value of the net assets acquired was recorded as goodwill, which is primarily attributed to the developed technologies and other intangibles as customer relationships and trade name. Immunetrics is primarily attributable to the Services segment of the Company. Goodwill acquired as part of Immunetrics acquisition has been assigned to a separate reporting unit and the assets and liabilities of Immunetrics are assigned to the same reporting unit, Immunetrics. This goodwill is not expected to be deductible for income tax purposes. Intangible assets consist of indefinite-lived intangible asset trade names and definite-lived intangibles as customer relationships, developed technologies, and covenants not to compete. We amortize purchased definite-lived intangible assets on a straight-line basis over their respective useful lives. The weighted-average life of the total acquired identifiable definite-lived intangible assets is 7.5 years. The following table presents the details of intangible assets acquired.
|  | Estimated useful life |  | Amount
Indefinite-lived: |  |  |  |
Trade names |  | Indefinite |  | $ | 1,800 |
Definite-lived: |  |  |  |
Customer relationships |  | 9 years |  | 3,780 |
Developed technologies |  | 5 years |  | 1,080 |
Covenants not to compete |  | 2 years |  | 30 |
Total definite-lived intangible assets |  |  |  | 4,890 |
Total intangible assets |  |  |  | $ | 6,690 |
The total acquisition-related costs which includes activities for Immunetrics acquisition for the years ended August 31, 2023, 2022, and 2021 were $3.3 million, $0.3 million, and none, respectively. These transactions costs are reflected in the Selling, general, and administrative expense line item within our consolidated statements of operations and comprehensive income as they were incurred. Estimated future amortization of finite-lived intangible assets for the next five years is as follows:
(in thousands) |  |
Years ending August 31, |  | Amount
2024 |  | $ | 580 |
2025 |  | $ | 580 |
2026 |  | $ | 580 |
2027 |  | $ | 580 |
2028 |  | $ | 535 |
Consolidated Supplemental Pro Forma Information The following unaudited consolidated supplemental pro forma information assumes that the acquisition of Immunetrics took place on September 1, 2021 for the income statement years ended August 31, 2023. These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Immunetrics to reflect the same expenses in the years ended August 31, 2023 and 2022. The adjustments include costs of acquisition directly attributable to Immunetrics of $2.9 million consists of $1.6 million of bonus compensation and $1.3 million of other professional fees, and amortization of intangibles including developed technologies acquired during the merger, assuming the fair-value adjustments applied on September 1, 2021, together with consequential tax effects.
|  | (Pro forma) 2023 * |  | (Pro forma) 2022
(in thousands) |  | (unaudited) |  | (unaudited)
Revenue |  | $ | 63,054 |  |  | $ | 57,010 |
Net income |  | $ | 11,422 |  |  | $ | 11,889 |
* Balances include actual results from acquisition date of June 16, 2023 through August 31, 2023.

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//805/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-20/tableOfContent + Details
Name: | us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration